Cliniques Universitaires Saint-Luc
- Address
- Hippokrateslaan 10, Batiment 54, 1200 Woluwe-Saint-Lambert, Belgium
Cliniques Universitaires Saint-Luc - Leading Belgian Academic Medical Center
Cliniques Universitaires Saint-Luc stands as a premier academic medical center in Belgium, conducting cutting-edge clinical research across diverse therapeutic areas. The institution demonstrates particular strength in oncology research, with extensive trials spanning breast cancer, lung cancer, colon cancer, biliary tract malignancies, and hematologic cancers. Their research portfolio encompasses both solid tumors and blood cancers, employing advanced treatment modalities including immunotherapy, targeted therapies, gene therapy, and CAR T-cell therapy.
- Comprehensive oncology trials including breast cancer (HER2-positive and hormone receptor-positive), lung cancer (NSCLC), gastrointestinal cancers, and hematologic malignancies (acute leukemias, lymphomas, multiple myeloma)
- Rare disease research focusing on genetic conditions such as hemophilia B gene therapy, lymphatic malformations with PIK3CA mutations, and pediatric ependymoma
- Inflammatory and autoimmune disease studies including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), lupus nephritis, and hidradenitis suppurativa
- Specialized programs in dermatology (psoriasis, vitiligo), respiratory conditions (chronic rhinosinusitis with nasal polyps), chronic kidney disease, and transplant medicine
The center demonstrates significant expertise in pediatric clinical research, conducting trials in acute myeloid leukemia, acute lymphoblastic leukemia, inflammatory bowel disease, and psoriasis in children and adolescents. Their research extends to critical care medicine with studies in trauma and sepsis, rare pulmonary conditions like sarcoidosis and invasive aspergillosis, and innovative approaches including precision medicine trials that utilize biomarker-driven patient selection and therapeutic drug monitoring strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 35 therapeutic areas and 15 of 717 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 698 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 151 by active trials.
lock +150 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG32trials
lock +88 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Cliniques Universitaires Saint-Luc
lock Showing 1 of 687 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD) | Bayer AG | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 717 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 62 | Unknown | 2015-07-16 | 2026-01-26 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.